<DOC>
	<DOCNO>NCT02406092</DOCNO>
	<brief_summary>Safety Study Rituximab Patients Non Hodgkin Lymphoma ( DLBCL &amp; FL )</brief_summary>
	<brief_title>Safety Study Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Patients specific type Non Hodgkin lymphoma 1 . Transformed lymphoma follicular lymphoma ( FL ) IIIB 2 . History malignancy could affect compliance protocol interpretation result . This include malignancy treat curative intent , unless malignancy remission without treatment &gt; /= 5 year prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>